Attached files

file filename
EX-99.1 - PRESS RELEASE ISSUED NOVEMBER 4, 2014 - UROLOGIX INCurologix143985_ex99-1.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (date of earliest event reported):  November 4, 2014

 

 

Urologix, Inc.

(Exact name of Registrant as Specified in its Charter)

 

Minnesota

(State Or Other Jurisdiction Of Incorporation)

 

000-28414 41-1697237
(Commission File Number) (I.R.S. Employer Identification No.)
   
14405 21st Avenue North
Minneapolis, MN
55447
(Address Of Principal Executive Offices) (Zip Code)

 

(763) 475-1400

Registrant’s Telephone Number, Including Area Code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

 

Items under Sections 1, 3, 4, 5, 6, 7 and 8 are not applicable and are therefore omitted.

 

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

 

Urologix, Inc. (the “Company”) hereby furnishes as Exhibit 99.1 a press release issued on November 4, 2014 disclosing material non-public information regarding the Company’s results of operations for the first fiscal quarter of fiscal year 2015 ended September 30, 2014.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
   
Exhibit No. Description
99.1 Press Release Issued on November 4, 2014.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  UROLOGIX, INC.
     
  By:   /s/ Gregory J. Fluet
    Gregory J. Fluet
Chief Executive Officer

 

Date: November 5, 2014